Dare bioscience, inc. (DARE)
Income statement / TTM
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Dec'14Sep'14Jun'14Mar'14Dec'13Sep'13Jun'13Mar'13
Revenue

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-

-

-

-

-

-

80

86

0

0

0

-

-

-

Operating expenses
General and administrative

5,850

5,265

4,923

4,780

4,629

4,655

4,610

4,488

3,807

2,704

3,819

2,772

2,414

5,331

6,113

9,061

11,661

11,224

10,959

10,446

9,758

8,587

7,555

6,341

5,704

6,166

0

0

0

Research and development

9,232

8,546

7,835

7,315

7,020

6,413

5,423

4,257

2,043

984

3,496

0

0

27,565

-

-

30,697

25,948

23,492

19,328

15,298

11,772

8,511

7,169

7,716

9,700

0

0

0

License Fee

433

533

683

550

637

625

0

0

0

-

-

-

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

Impairment of goodwill

-

-

-12

-12

-

5,187

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Total operating expenses

15,515

14,344

13,442

12,645

12,288

16,882

23,062

21,774

18,629

11,180

7,315

5,988

5,876

18,535

23,290

33,330

42,358

37,172

34,451

29,774

25,056

20,359

16,066

13,510

13,420

15,866

0

0

0

Loss from operations

-15,515

-14,344

-13,442

-12,645

-12,288

-16,882

-23,062

-21,774

-18,629

-11,180

0

0

0

-

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

Interest income (expense)

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Interest income

-

-

-

-

-

-

-

-

-

-

-

-

-

86

-

-

23

10

12

10

11

9

6

4

2

2

0

0

0

Interest expense

-

-

-

-

-

-

-

-

-

-

-

-

-

2,245

-

-

2,381

2,432

1,906

1,588

1,343

1,083

1,350

1,537

1,595

1,487

0

0

0

Loss on extinguishment of debt

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-

-

-

-

Decrease in value of preferred stock warrant liability

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-504

-462

-455

-475

-202

0

0

0

Other income

51

81

128

150

162

143

109

-234

-295

-322

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-1,283

0

0

0

Total other expense, net

-

-

-

-

-

-

-

-

-

-

-

-

-

-2,151

-

-

-2,358

-2,422

-1,894

-1,578

-3,825

-3,063

0

0

0

-

-

-

-

Net loss

-15,464

-14,263

-13,313

-12,495

-12,125

-16,738

-22,953

-22,008

-18,924

-11,503

-7,316

-5,703

-5,572

-18,871

-24,642

-35,176

-44,716

-39,594

-36,345

-31,352

-28,848

-23,342

0

0

0

-

-

-

-

Deemed dividend from trigger of round down provision feature

-

-

0

0

-

-

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net loss to common shareholders

-

-

0

0

-

-

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-17,143

0

0

0

Foreign currency translation adjustments

-36

-5

-34

-37

-57

-78

0

0

0

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Comprehensive loss

-16,290

-15,059

-14,137

-13,322

-12,182

-16,817

-23,021

-22,068

-18,956

-11,521

0

0

0

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Loss per common share - basic and diluted (in usd per share)

-0.18

-0.21

-0.20

-0.29

-0.27

-0.14

-0.23

-0.32

-0.88

4.71

-0.33

-0.55

-0.27

-0.17

-0.02

-

-0.49

-0.39

-0.39

-0.37

-0.41

-0.37

-0.28

-0.44

-3.70

-4.45

-4.40

-7.96

-9.09

Weighted average number of common shares outstanding:
Basic

-

-

-

-

-

-

-

-

-

-

-

910

910

-

820

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Diluted

-

-

-

-

-

-

-

-

-

-

-

-

-

-

830

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Basic and diluted (in shares)

23,799

18,105

16,683

16,105

11,422

11,400

11,422

11,422

8,684

-

4,986

-

-

28,724

-

-

27,362

27,346

27,307

26,690

20,350

20,125

20,124

16,883

786

782

726

614

612